2020
DOI: 10.1093/ofid/ofaa022
|View full text |Cite
|
Sign up to set email alerts
|

Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis C Treatment: A Randomized Controlled Trial

Abstract: Background Oral direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) became government subsidized in Australia in March 2016, bringing the interferon era to a close. The ideal monitoring schedule for patients receiving DAAs is unclear. Methods This study is a randomized controlled trial comparing standard with minimal monitoring in adults receiving sofosbuvir-based therapy for HCV genotypes 1 or 3. Exclusion crit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
6
0
1

Year Published

2021
2021
2025
2025

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 10 publications
0
6
0
1
Order By: Relevance
“…To increase access, treatment through prenatal care providers rather than liver specialists, use of an effective pan-genotypic regimen in pregnancy, and decreased treatment monitoring protocols are proposed approaches that may facilitate treatment engagement and adherence and deserve further study. 16,26 LDV/SOF treatment is just 12 weeks long, and safety data from the phase 1 trial supports ongoing investigation in oral therapy for chronic HCV infection during pregnancy. 19 Treatment during pregnancy for chronic HCV infection may represent an important opportunity to combat rising HCV rates among people with childbearing potential and children with perinatal acquisition of HCV.…”
Section: Discussionmentioning
confidence: 89%
“…To increase access, treatment through prenatal care providers rather than liver specialists, use of an effective pan-genotypic regimen in pregnancy, and decreased treatment monitoring protocols are proposed approaches that may facilitate treatment engagement and adherence and deserve further study. 16,26 LDV/SOF treatment is just 12 weeks long, and safety data from the phase 1 trial supports ongoing investigation in oral therapy for chronic HCV infection during pregnancy. 19 Treatment during pregnancy for chronic HCV infection may represent an important opportunity to combat rising HCV rates among people with childbearing potential and children with perinatal acquisition of HCV.…”
Section: Discussionmentioning
confidence: 89%
“…Few studies have evaluated simplified HCV treatment delivery. 11 , 12 , 13 Most reduced the frequency of on-treatment laboratory monitoring but still required pre-treatment HCV genotyping and medication dispensation at multiple timepoints. 11 , 13 Most comparable to MINMON is the SMART-C trial, a randomised trial comparing standard to simplified monitoring using a fixed-dose combination of glecaprevir and pibrentasvir, which required three tablets to be taken orally daily for 8 weeks.…”
Section: Discussionmentioning
confidence: 99%
“… 11 , 12 , 13 Most reduced the frequency of on-treatment laboratory monitoring but still required pre-treatment HCV genotyping and medication dispensation at multiple timepoints. 11 , 13 Most comparable to MINMON is the SMART-C trial, a randomised trial comparing standard to simplified monitoring using a fixed-dose combination of glecaprevir and pibrentasvir, which required three tablets to be taken orally daily for 8 weeks. 12 However, this trial excluded people with cirrhosis, included only 27 (7%) individuals living with HIV and HCV, and required pre-treatment HCV genotyping.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The introduction of direct acting antiviral (DAA) regimens has revolutionised the management of hepatitis C virus (HCV) infection. The high efficacy and low toxicity of these regimens mean that on-treatment virological monitoring is no longer required and that the monitoring for toxicity is minimised [ 1 ]. DAA therapy has improved HCV management in low- and middle-income countries (LMIC), which have the highest global HCV burden [ 2 ].…”
Section: Introductionmentioning
confidence: 99%